These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25034619)

  • 41. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Towards better patient care: drugs to avoid in 2014.
    Prescrire Int; 2014 Jun; 23(150):161-5. PubMed ID: 25121155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse Drug Reactions for Medicines Newly Approved in Japan from 1999 to 2013: Hypertension and Hypotension.
    Nagayama T; Nishida M; Hizue M; Ogino Y; Fujiyoshi M
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):306-12. PubMed ID: 26407539
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparisons of Usual Dose of Pharmaceutical Products Used in Japan and United States: Can Differences Be Explained by Pharmacokinetics Alone?
    Takayanagi R; Endo Y; Kimura K; Yamada Y
    Ther Innov Regul Sci; 2019 Sep; 53(5):684-690. PubMed ID: 30380917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan.
    Ishiguro A; Yagi S; Uyama Y
    J Hum Genet; 2013 Jun; 58(6):313-6. PubMed ID: 23657427
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ways to minimize adverse drug reactions. Individualized doses and common sense are key.
    Cohen JS
    Postgrad Med; 1999 Sep; 106(3):163-8, 171-2. PubMed ID: 10494273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

  • 48. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Parameter-finding studies of photodynamic therapy for approval in Japan and the USA.
    Kawase Y; Iseki H
    Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):434-45. PubMed ID: 24284097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An approach for modeling noncancer dose responses with an emphasis on uncertainty.
    Price PS; Keenan RE; Swartout JC; Gillis CA; Carlson-Lynch H; Dourson ML
    Risk Anal; 1997 Aug; 17(4):427-37. PubMed ID: 9323872
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Idiosyncratic toxicity: a convergence of risk factors.
    Ulrich RG
    Annu Rev Med; 2007; 58():17-34. PubMed ID: 16958561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medication-induced violence others towards.
    Prescrire Int; 2014 Jun; 23(150):153-5. PubMed ID: 25121148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmaceutical salts: a summary on doses of salt formers from the Orange Book.
    Saal C; Becker A
    Eur J Pharm Sci; 2013 Jul; 49(4):614-23. PubMed ID: 23747999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A molecular and phenotypic integrative approach to identify a no-effect dose level for antiandrogen-induced testicular toxicity.
    Ludwig S; Tinwell H; Schorsch F; Cavaillé C; Pallardy M; Rouquié D; Bars R
    Toxicol Sci; 2011 Jul; 122(1):52-63. PubMed ID: 21525395
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay?
    Yamada T; Kusama M; Hirai Y; Arnold F; Sugiyama Y; Ono S
    Ann Pharmacother; 2010 Dec; 44(12):1976-85. PubMed ID: 21098757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The credibility of the FDA.
    Blankfield RP
    Eur J Prev Cardiol; 2013 Dec; 20(6):992-4. PubMed ID: 23867140
    [No Abstract]   [Full Text] [Related]  

  • 58. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013.
    Suh HY; Peck CC; Yu KS; Lee H
    Drug Des Devel Ther; 2016; 10():4005-4016. PubMed ID: 27994442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
    Hasegawa R; Koizumi M; Hirose A
    Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials.
    Kornbrust D
    Nucleic Acid Ther; 2019 Jun; 29(3):123-125. PubMed ID: 30817231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.